22 August 2025 in Nature Protocols
IHIngvild Comfort Hvinden
+7
14 June 2025 in Journal of Pharmaceutical and Biomedical Analysis
We investigate the potential of Spatially Offset Raman Spectroscopy (SORS) as a rapid, non-invasive screening tool deployable in the field to detect diethylene glycol (DEG) and ethylene glycol (EG) in medicinal syrups within closed containers. Measurements were performed on neat propylene glycol (PG) and glycerol, key components of many medicinal syrups, as well as marketed medicinal syrup formulations spiked with DEG and EG at various concentration levels to assess the technique's limit of detection in real-life samples. SORS was able to detect these down to ∼0.5 % concentration level in neat PG for both DEG and EG compounds and ∼1 % concentration level for DEG and EG in neat glycerol. The DEG and EG detection thresholds for the marketed formulations measured through original bottles was ∼1 %, for Benylin (active ingredient: Glycerol) and Piriteze (active ingredient: Cetirizine Hydrochloride). For Calpol (active ingredient: Paracetamol) the detection limit was higher, ∼2 % for EG and ∼5 % for DEG. Although not reaching the International Pharmacopeial 0.1 % detection threshold currently required for purity checks for human consumption, the method can still be used to detect products where DEG or EG has been wrongly used instead of PG or glycerol or if present in large quantities. The technique could also be used for raw material identification testing to ensure no mislabelling has occurred in pre-production stages and as a screening device in distribution chains to detect major deviations from permitted content in non-diffusely scattering, clear formulations, to help prevent serious adverse outcomes, such as acute renal failure and deaths.
22 June 2025 in The Journal of Pathology
AMAlbert Antao Nobre de Menezes
Albert Antao Nobre de Menezes
+17
The CpG island methylator phenotype (CIMP) occurs in many colorectal cancers (CRCs). CIMP is closely associated with global hypermethylation and tends to occur in proximal tumours with microsatellite instability (MSI), but its origins have been obscure. A few CRCs carry oncogenic (gain‐of‐function) mutations in isocitrate dehydrogenase IDH1 . Whilst IDH1 is an established CRC driver gene, the low frequency of IDH1 ‐mutant CRCs (about 0.5%) has meant that the effects and molecular covariates of those mutations have not been established. We first showed computationally that IDH2 is also a CRC driver. Using multiple public and in‐house CRC datasets, we then identified IDH mutations at the hotspots ( IDH1 codons 132 and IDH2 codons 140 and 172) frequently mutated in other tumour types. Somatic IDH mutations were associated with BRAF mutations and expression of mucinous/goblet cell markers, but not with KRAS mutations or MSI. All IDH‐mutant CRCs were CIMP‐positive, mostly at a high level. Cell and mouse models showed that IDH mutation was plausibly causal for DNA hypermethylation. Whilst the aetiology of hypermethylation generally remains unexplained, IDH‐mutant tumours did not form a discrete methylation subcluster, suggesting that different underlying mechanisms can converge on similar final methylation phenotypes. Although further analysis is required, IDH mutations may be the first cause of hypermethylation to be identified in a common cancer type, providing evidence that CIMP and DNA methylation represent more than aging‐related epiphenomena. Cautious exploration of mutant IDH inhibitors and DNA demethylating agents is suggested in managing IDH‐mutant CRCs. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
10 June 2026 in Cell Death Discovery
Radiotherapy is widely used in the treatment of lung cancer; a number of intrinsic and extrinsic mechanisms of resistance exist, including hypoxia. Targeting metabolic pathways that support redox homeostasis has been proposed as a strategy to enhance radiosensitivity. The serine synthesis pathway enzyme, phosphoglycerate dehydrogenase (PHGDH), has been implicated in resistance to several anticancer therapies; however, its role in radiotherapy response is poorly defined. We show that PHGDH expression positively correlates with established hypoxia gene expression signatures in lung adenocarcinoma and squamous cell carcinoma patient datasets and is induced under hypoxia (<0.1% O 2 ) in lung cancer cell lines. Hypoxic induction of PHGDH appears mediated by both HIF-1 and PERK signalling, linking PHGDH regulation to hypoxia and the unfolded protein response. Using CRISPR-Cas9 PHGDH knockout models, we demonstrate that loss of PHGDH does not enhance radiosensitivity in normoxia or hypoxia when extracellular serine and glycine are available at physiological or supraphysiological concentrations. Radiosensitisation is observed only under complete serine/glycine deprivation. Unexpectedly, PHGDH loss confers increased tolerance to hypoxic stress, associated with elevated glycolytic flux, increased lactate production, accelerated HIF-1α stabilisation and enhanced expression of hypoxia-inducible genes. Overall, these data indicate that targeting PHGDH alone is unlikely to impact radioresistance in lung cancer under physiologically relevant nutrient conditions and may instead promote metabolic adaptation to hypoxia. This highlights the importance of microenvironmental context when evaluating metabolic targets for combination with radiotherapy.
11 June 2025 in Research Square
Maintaining cold-chain integrity is vital for vaccines to ensure they remained within the recommended temperature limits to ensure stability and avoid degradation as storage temperature is one of the key factors contributing to rendering products substandard or ‘out of specification’. Heat-exposed vaccines closely resemble the chemical composition of the stable product making them very difficult to detect and testing as such is not routinely carried out at various points in the supply chain due to the lack of tools to identify effects of heat exposure in the field, a particular issue in countries with high-temperature climates. Here, we propose rapid and low-cost tests based on simple glucose assays to detect heat-exposed degraded sucrose-containing vaccines through its inherent gradual conversion to glucose at elevated temperatures. Bioluminescent and colorimetric assays and a clinical biochemical analyser for urine samples could successfully determine effects of heat exposure by detecting a significant increase in glucose levels. We show that this increase in glucose also correlates with the loss of vaccine potency. When vaccines were incubated at 37 and 45°C, the bioluminescent assay was able to detect an increase in glucose levels from 12 hours of heat exposure. The biochemical analyser could successfully detect if a COVID-19 vaccine had been exposed to 37 and 45°C. Most importantly, the colorimetric assay has the advantage of noticing a colour change by eye upon simply mixing the vaccine with a reagent without the need for a plate reader or any other sophisticated devices. To our knowledge, this is the first device-free test of its kind to determine the heat-exposed vaccines, making it an ideal test for deploying at various points in the supply chain in low- and middle-income countries to ensure the integrity of vaccine cold-chain. Although this test does not replace the more definitive potency assays, it could initially be used as a rapid and low-cost test to identify substandard sucrose-containing vaccines within supply chains, in support of WHO’s Prevent, Detect, and Respond strategy.